Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4 - PubMed (original) (raw)

Randomized Controlled Trial

. 2013 Jul;131(7):843-50.

doi: 10.1001/jamaophthalmol.2013.4412.

Emily Y Chew, John Paul SanGiovanni, Frederick L Ferris, Wai T Wong, Elvira Agron, Traci E Clemons, Robert Sperduto, Ronald Danis, Suresh R Chandra, Barbara A Blodi, Amitha Domalpally, Michael J Elman, Andrew N Antoszyk, Alan J Ruby, David Orth, Susan B Bressler, Gary E Fish, George B Hubbard, Michael L Klein, Thomas R Friberg, Philip J Rosenfeld, Cynthia A Toth, Paul Bernstein

Collaborators, Affiliations

Randomized Controlled Trial

Age-Related Eye Disease Study 2 (AREDS2) Research Group et al. JAMA Ophthalmol. 2013 Jul.

Abstract

Importance: Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020.

Objective: To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery.

Design, setting, and patients: The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration.

Interventions: Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration.

Main outcomes and measures: Cataract surgery was documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery.

Results: A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24%. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95% CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95% CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95% CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin).

Conclusions and relevance: Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss.

Trial registration: clinicaltrials.gov Identifier: NCT00345176.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.

Figure 1.

Flow Diagram of Participants in the Age-Related Eye Disease Study 2 of Lutein/Zeaxanthin Treatment for Age-Related Cataract DHA indicates docosahexaenoic acid; EPA, eicosapentaenoic acid.

Figure 2.

Figure 2.

Progression to Cataract Surgery in Age-Related Eye Disease Study 2 Participants by Treatment (Lutein/Zeaxanthin vs No Lutein/Zeaxanthin)

Figure 3.

Figure 3.

Effect of Lutein/Zeaxanthin Supplementation on the Progression of Cataract Stratified by Dietary Intake of Lutein/Zeaxanthin

Figure 4.

Figure 4.

Effect of Lutein/Zeaxanthin Supplementation on Moderate Vision Loss (3 or More Lines) From Baseline Stratified by Dietary Intake of Lutein/Zeaxanthin IQR indicates interquartile range.

Similar articles

Cited by

References

    1. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11(2):67–115. - PubMed
    1. Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–851. - PMC - PubMed
    1. Congdon N, O’Colmain B, Klaver CC, et al.; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–485. - PubMed
    1. Congdon N, Vingerling JR, Klein BE, et al.; Eye Diseases Prevalence Research Group. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol. 2004;122(4):487–494. - PubMed
    1. Leske MC, Chylack LT Jr, Wu SY. The Lens Opacities Case-Control Study: risk factors for cataract. Arch Ophthalmol. 1991;109(2):244–251. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources